Michael Hallek to Pyrimidines
This is a "connection" page, showing publications Michael Hallek has written about Pyrimidines.
Connection Strength
1.896
-
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
Score: 0.438
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
Score: 0.412
-
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
Score: 0.320
-
New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019 03; 33(3):576-587.
Score: 0.106
-
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
Score: 0.105
-
Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
Score: 0.100
-
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
Score: 0.097
-
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
Score: 0.096
-
Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 11; 282(5):415-428.
Score: 0.093
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.029
-
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
Score: 0.026
-
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. Biomed Res Int. 2018; 2018:1023490.
Score: 0.025
-
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
Score: 0.024
-
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 09; 178(6):949-953.
Score: 0.024